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adult CHD were retrospectively included. Adverse events were
assessed using the Bergersen classiﬁcation.
Results 174 stents were implanted during 132 procedures in
127 patients by 6main operators in 9 centers. Patients were
aged 15.7± 15.1 years old (min 5 day-old -max 70 years old). Six-
teen types of procedures were identiﬁed. Main indications were
transcatheter pulmonary valve replacement (29 patients, 23.0%),
pulmonary artery branches angioplasty (34 patients, 27.0%), aortic
(re)coarctation stenting (37 patients, 29.4%) and ductus arterio-
sus stenting (11 patients, 8.7%). 18 patients (14.3%) were under
one y.o and 35 (27.8%) were over 18 y.o. Main pathologies were
tetralogy of Fallot and variants (ACC-CHD 8.3, n = 45, 35.7%), and
aortic coarctation (ACC-CHD 9.2, n = 36, 28.6%). More than 1 stent
was implanted in 32 procedures (24.4%, max. 5 stents). Main stents
implanted were the CP stent (33.0%), EV3 LD max (22.0%), Valeo
(16.2%) and valved stents (15.0%). 98.5% procedures were con-
sidered as successful. Serious adverse events were observed in
12.9%. After multivariate adjustment, only procedure type was
related to the risk of total adverse events (OR: 3.0, 95%CI 1.1—7.9)
but not to stent related adverse events. Age, weight, center,
operator, type of stents, stent diameter, genetic disorder and
type of CHD were not signiﬁcantly related to the risk of adverse
events.
Conclusion Stents are used in various CHD catheterization proce-
dures, from infancy to adult age. Adverse events rate is signiﬁcant
and seems related to the type of procedure.
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Objectives Congenital mitral valve stenosis (CMVS) is a hetero-
geneous group of lesions that can be isolated or part of left heart
obstructive syndrom. Historically, mitral valve surgery has been
associated with signiﬁcant morbidity and mortality. Surgical tech-
niques have recently improved. We review here a single-center
experience in mitral valve (MV) surgery for CMVS.
Patients Between 1975 and 2013, 50 pts underwent MV surgery
for CMVS. Six (12%) were adults (> 18 yrs) and 18 were < 2 yrs (36%).
Median age was 3 yrs (19 d—30 yrs, mean 6.3 yrs), median weight
13 kg (2.7—80 kg, mean 19.2 kg). In 35 pts, CMVS was part of left
heart obstructive syndrome, with 1 or more previous non-MV surgery
in 25. Among the 15 pts with ‘‘isolated’’ CMVS, 2 had previous non-
MV surgery. Two pts had previous mitral valvuloplasty in another
center.
Results First choice MV surgery was valvuloplasty in 48 pts, pros-
thetic valve replacement (MVR) in 2. In the valvuloplasty group,
14 pts were reoperated with a median delay of 11mo (mean 22mo,
19 d—16.6 yrs). Second surgery was MVR in 3, valvuloplasty in 11.
Five pts had a 3rd surgery (3MVR, 3 valvuloplasty), 2 had a 4th
surgery (redo MVR). There were 6 deaths (overall mortality 12%):
2 after ﬁrst surgery (1 valvuloplasty, 1MVR, respectively 8 and
14 days postop), 4 after the second surgery (24 days and 3.5mo
after valvuloplasty, 30 days and 31 yrs after MVR). Risk factors for
postoperative death were: presence of supravalvular lesions (left
superior vena cava in the coronary sinus and/or supramitral ring,
P < 0.04), surgery for supravalvular lesions (P < 0.04), longer cardiac
bypass time (P < 0.03) and longer ICU stay duration (P < 0.01). Risk
factors for reoperation were younger age (P = 0.008) and low weight
(P < 0.04) at ﬁrst surgery.
Conclusion Valvuloplasty as ﬁrst-choice surgery for CMVS carries
an acceptable initial mortality but a relatively high rate of reop-
erations (29%). Iterative plasty is possible but mortality is higher
(18%).
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